Azithromycin for ocular toxoplasmosis
Related Experiment Video
Updated: Oct 26, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
Published on: January 12, 2022
A Rothova1, L E Bosch-Driessen, N H van Loon
1Department of Ophthalmology, FC Donders Institute, Academic Hospital Utrecht, Netherlands.
Aims:
To investigate the efficacy of azithromycin in patients with ocular toxoplasmosis.
Methods:
11 immunocompetent patients with ocular toxoplasmosis were treated with azithromycin (500 mg the first day, followed by 250 mg/day for 5 weeks). Ocular and systemic examinations were performed during active retinitis episodes and all patients were followed for at least 1 year.
Results:
The intraocular inflammation disappeared within 4 weeks in seven patients, including two cases with progressive retinitis despite previous treatment with pyrimethamine, sulphadiazine, and folinic acid. Recurrence of retinitis occurred in three patients (27%) within the first year of follow up. No systemic side effects of azithromycin were encountered.
Conclusion:
These results indicate that although azithromycin cannot prevent recurrent disease it may be an effective alternative for patients with ocular toxoplasmosis who cannot tolerate standard therapies.
Related Concept Videos
Toxoplasmosis
Trichomoniasis
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Microbiome of the Eye
Ophthalmic Drug Delivery Systems